Recombinant Human Universal Type I IFN Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11020-IF

IFN-alpha-2A/IFN-alpha-1B
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11020-IF-010
11020-IF-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

P01563.1

Conjugate

Unconjugated

Applications

Bioactivity

View all IFN-alpha Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human IFN-alpha protein
Human IFNA-2A
(Cys24-Gln85)
Accession # P01563.1		 Human IFNA-1B
(Ile87-Glu189)
Accession # CAA23799.1
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Cys24

Predicted Molecular Mass

19 kDa

SDS-PAGE

16-22 kDa, under reducing conditions.

Activity

Measured in anti-viral assays using HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. Meager, A. (1987) in Lymphokines and Interferons, a Practical Approach. Clemens, M.J. et al. (eds): IRL Press. 129.
The ED50 for this effect is 6.00-60.0 pg/mL.

Scientific Data Images for Recombinant Human Universal Type I IFN Protein, CF

Recombinant Human Universal Type I IFN Protein Bioactivity.

Recombinant Human Universal Type I IFN (Catalog # 11020-IF) demonstrates anti-viral activity in HeLa human cervical epithelial carcinoma cells infected with encephalomyocarditis (EMC) virus. The ED50 for this effect is 6.00-60.0 pg/mL

Recombinant Human Universal Type I IFN Protein SDS-PAGE.

2 μg/lane of Recombinant Human Universal Type I IFN Protein (Catalog # 11020-IF) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 16-22 kDa.

Formulation, Preparation and Storage

11020-IF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IFN-alpha

Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors (1). Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology (2-4). Structurally, type I IFNs belong to the class of five helical-bundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds (5). The extracellular domain (ECD) of mature human universal Type I IFN is a hybrid of the N-terminal residues of IFNA-2A and C-terminal residues of IFNA-1B. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) (6, 7). Individual IFNA subtypes are known to display unique efficacies to viral protection, and IFNA1 exhibits low potency, determined by both antiviral and antiproliferative activities (8). Conversely, hybrid IFNA molecules, similar to universal Type I IFN, exhibit high specific activity across multiple species (9, 10). These molecules were developed to help study the biology of the IFN system in various animal species (11). Human IFNA1 was the first IFNA to be purified and has been tested as a treatment for various diseases (12-14).

References

  1. Pestka, S. et al. (1987) Annu Rev Biochem. 56:727.
  2. Goeddel, D.V. et al. (1980) Nature 287:411.
  3. Matsumiya, T. et al. (2007) J. Immunol. 179:4542.
  4. Schreiber, G. and J. Piehler (2015) Trends Immunol. 36:139.
  5. Wittling, M.C. et al. (2021) Front Immunol. 11:605673.
  6. van Pesch, V. et al. (2004) J. Virol. 78:8219.
  7. James, C.M. et al. (2007) Vaccine. 25(10):1856.
  8. Moll, H.P. et al. (2011) Cytokine. 53:52.
  9. Horisberger, M.A. and de Staritzky, K. (1987) J Gen Virol. 68:945.
  10. Hu, R. et al. (1999) J Immunol. 163:854.
  11. Horisberger, M.A. and Di Marco, S. (1995) Pharmacol Ther. 66:507.
  12. Rubinstein, M. et al. (1978) Science. 202:1289.
  13. Harper, M.S. et al. (2015) PLOS Pathogens 11:e1005254.
  14. George, J. and Mattapallil, J.J. (2018) Front Immunol. 9:299.

Long Name

Interferon alpha

Alternate Names

IFNalpha, LeIF D

Entrez Gene IDs

3440 (Human)

Gene Symbol

IFNA2

UniProt

P01563.1 (Human)

Additional IFN-alpha Products

Product Documents for Recombinant Human Universal Type I IFN Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human Universal Type I IFN Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.